|
Canadian Drugmakers Expect Higher Costs From EU Proposals
A report conducted by Canada’s generics industry shows changes to the country’s drug patent system would add almost $3 billion annually to its drug costs.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives